Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

ESMO 2026 | DASL-HiCaP: darolutamide with ADT and RT in very high-risk localized prostate cancer

Tamim Niazi • 26 Oct 2026

ESMO 2026

Genitourinary Cancer Prostate Cancer Darolutamide

DASL-HiCaP

Tamim Niazi, MD, McGill University, Montreal, Canada, discusses the interim analysis of the Phase III DASL-HiCaP trial (ANZUP1801; NCT04136353), which evaluated adding darolutamide to androgen deprivation therapy (ADT) and locoregional radiotherapy (RT) in very high-risk localized or biochemically persistent or recurrent prostate cancer. Addition of darolutamide significantly improved metastasis-free survival compared with placebo, with a manageable safety profile. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.